ICU Medical (NASDAQ:ICUI) Issues FY 2026 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 7.750-8.450 for the period, compared to the consensus EPS estimate of 7.410. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of recent research reports. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday. Piper Sandler raised their price target on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. KeyCorp lifted their price target on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ICU Medical presently has an average rating of “Moderate Buy” and a consensus price target of $175.67.

ICU Medical Stock Performance

Shares of ICUI stock traded down $1.89 during trading on Thursday, hitting $149.74. The company’s stock had a trading volume of 550,391 shares, compared to its average volume of 262,663. The business has a fifty day moving average of $149.17 and a 200-day moving average of $135.59. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62. ICU Medical has a 52 week low of $107.00 and a 52 week high of $164.35. The company has a market cap of $3.70 billion, a PE ratio of -483.02 and a beta of 0.79.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The firm had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, research analysts anticipate that ICU Medical will post 4.11 earnings per share for the current year.

Institutional Investors Weigh In On ICU Medical

A number of large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its position in ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after purchasing an additional 229 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock valued at $1,772,000 after buying an additional 560 shares during the last quarter. United Services Automobile Association purchased a new stake in ICU Medical during the first quarter valued at approximately $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in ICU Medical by 32.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after acquiring an additional 16,680 shares during the period. Finally, Intech Investment Management LLC grew its position in shares of ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after acquiring an additional 3,326 shares during the period. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.